17.75

1.93% -0.35

After Hours: 17.75

Travere Therapeutics Inc (TVTX)

Overview News Price History Option Chain Financials Why TVTX Down? Discussions Forecast Stock Split

Travere Therapeutics Inc stock is traded at $17.75, with a volume of 863.48K. It is down -1.93% in the last 24 hours and up +16.55% over the past month. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.

Previous Close:

$18.10

Open:

$18.05

24h Volume:

863.48K

Relative Volume:

0.50

Market Cap:

$1.38B

Revenue:

$198.84M

Net Income/Loss:

$-111.40M

P/E Ratio:

-3.927

EPS:

-4.52

Net Cash Flow:

$-322.28M

1W Performance:

-3.38%

1M Performance:

+16.55%

6M Performance:

+183.55%

1Y Performance:

+154.66%

1-Day Range:

$17.32

$18.10

1-Week Range:

$16.77

$18.90

52-Week Range:

$5.12

$19.25

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name

Travere Therapeutics Inc

Sector

Healthcare (1182)

Industry

Biotechnology (680)

Phone

888-969-7879

Address

3611 VALLEY CENTRE DR, SAN DIEGO

Employee

380

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

TVTX's Discussions on Twitter

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy
Nov-20-23	Initiated	Citigroup	Neutral
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform
Jul-21-23	Initiated	JP Morgan	Overweight
Jun-07-23	Resumed	Piper Sandler	Neutral
May-22-23	Initiated	TD Cowen	Outperform
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform
Dec-14-22	Initiated	Stifel	Hold
Dec-05-22	Initiated	Wells Fargo	Overweight
Sep-21-22	Initiated	Bryan Garnier	Sell
Jul-14-22	Resumed	Canaccord Genuity	Buy
Mar-31-22	Initiated	Piper Sandler	Overweight
Feb-28-22	Initiated	H.C. Wainwright	Buy
May-26-21	Downgrade	Wedbush	Outperform → Neutral

View All

Travere Therapeutics Inc Stock (TVTX) Latest News

04:19 AM

Vanguard Group Inc's Strategic Acquisition in Travere Therapeuti - GuruFocus.com

04:19 AM

Nov 04, 2024

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates - MSN

Nov 04, 2024

Travere Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Nov 04, 2024

Nov 03, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Holdings Raised by Emerald Mutual Fund Advisers Trust - MarketBeat

Nov 03, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Scotiabank Analyst Says - Defense World

Nov 03, 2024

Nov 01, 2024

Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Barclays Analyst Says - MarketBeat

Nov 01, 2024

Evercore ISI raises Travere Therapeutics target to $33 By Investing.com - Investing.com Australia

Nov 01, 2024

Travere Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Nov 01, 2024

Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024